-
Mashup Score: 4
This editorial refers to ‘Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid-lowering drugs’, by I. Engebretse
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs - 9 month(s) ago
AbstractAims. In clinical practice, many patients do not reach the recommended treatment targets for LDL-cholesterol levels. We aimed to examine treatment patte
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of #LLT https://t.co/awCDGLRa3W
-
-
Mashup Score: 0Potential Novel RNA-Targeting Agents for Effective... : Journal of Cardiovascular Pharmacology - 9 month(s) ago
is article was to critically review the evidence from clinical development studies to date on the efficacy and safety of new RNA-based therapeutics for targeted lowering of Lp(a). PubMed/MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov were searched without any language or date restriction up to November 5, 2022, and a total of 12 publications and 22 trial records were included. Several drugs were found that are currently in various stages of clinical development, such as the antisense oligonucleotide pelacarsen and the small interfering RNA molecule olpasiran and drugs coded as SLN360 and LY3819469. Among them, pelacarsen has progressed the most, currently reaching phase 3. All these drugs have so far shown satisfactory pharmacokinetic properties, consistently high and stable, dose-dependent efficacy in lowering Lp(a) even by more than 90%, with an acceptable safety profile in subjects with highly elevated Lp(a). In addition, reports of early clinical trials with pelacarsen imp
Source: journals.lww.comCategories: Cardiologists, Latest HeadlinesTweet-
Potential Novel RNA-Targeting Agents for Lp(a) inhibition. #LLT https://t.co/W7VvTfTyRG
-
-
Mashup Score: 4Cardiovascular events in patients treated with bempedoic acid versus placebo: systematic review and meta-analysis - 9 month(s) ago
AbstractAims. Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular mortality and morbidity. Bempedoic acid represents a promising n
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
Cardiovascular events in patients treated with bempedoic acid versus placebo: systematic review & meta-analysis https://t.co/dJnr7qBoln
-
Cardiovascular events in patients treated with bempedoic acid versus placebo. #BA #LLT #MA https://t.co/ozb2mwFuqA
-
-
Mashup Score: 1Modulation and personalization of therapy after acute coronary syndromes: the road to precision - 9 month(s) ago
The mortality and morbidity associated with acute coronary syndromes (ACSs) have declined markedly over the past 50 years, mainly due to the introduction of the
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
Modulation and personalization of therapy after acute coronary syndromes: the road to precision. #ACS #DAPT #LLT #SAPT #Colchicine #ImmunoModulation https://t.co/XWv4J77dKb
-
-
Mashup Score: 19
Original Article from The New England Journal of Medicine — Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Source: www.nejm.orgCategories: Cardiologists, Latest HeadlinesTweet-
#Pitavastatin to Prevent Cardiovascular Disease in #HIV. A new entry after #Prava and #Rosuva but not reimbursed in France. #LLT #lipids https://t.co/CfEpU3kd7Z
-
-
Mashup Score: 1Chez qui et pourquoi doser la Lp(a) ? - 10 month(s) ago
La Lp(a)Publié le 20 juin 2023- Durée : 00:06:24Dr Pierre Sabouret, Cardiologue à Paris Attention, pour des raisons réglementaires ce site est réservé aux professionnels de santé. pour voir la suite, inscrivez-vous gratuitement. Si vous êtes déjà inscrit,connectez vous : Se connecter Si vous n’êtes pas encore inscrit au site,inscrivez-vous gratuitement : Je m’inscris
Source: Cardiologie PratiqueCategories: Cardiologists, Latest HeadlinesTweet-
All that you want to know about Lp(a) without asking at #AXISTV https://t.co/dGdqKu0RPt #LLT #lipids
-
-
Mashup Score: 0Modulation and personalization of therapy after acute coronary syndromes: the road to precision - 10 month(s) ago
The mortality and morbidity associated with acute coronary syndromes (ACSs) have declined markedly over the past 50 years, mainly due to the introduction of the
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Modulation and personalization of therapy after acute coronary syndromes: the road to precision | European Heart Journal. Thanks to @FrancescoPaneni for the kind invitation #EHJ #LLT #DAPT #ImmunoModulation #CCS #ACS https://t.co/2jj7hTAdE6
-
-
Mashup Score: 0Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective - 10 month(s) ago
AbstractAims. Long-term disease progression following myocardial infarction (MI) is not well understood. We examined the risk of subsequent cardiovascular event
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Cardiovascular risk in post #ACS nationwide real world data. Many recurrent events during the first year. Therefore, please act early and use the #upfront strategy for #LLT https://t.co/cQ6MOxJBhM
-
-
Mashup Score: 3ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis - Current Atherosclerosis Reports - 11 month(s) ago
Purpose of Review Elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins (TRLs) or remnants are important risk factors for the development of atherosclerotic cardiovascular disease (ASCVD). The ongoing challenge of not being able to achieve recommended LDL-C targets despite maximally tolerated lipid-lowering therapy (LLT) has led to the development of novel…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet-
#ANGPTL3 the new entry ? #Lipids #LLT https://t.co/e2CecdjHcY
-
Adherence to statin therapy: it seems we know everything, yet we do nothing #LLT by 2 friends and experts ☀️ https://t.co/ObaaNxjAnu